Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

Platelet Disorder Clinical Trial

Official title:
Study on Avatrombopag for the Promotion of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Status Recruiting

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of avatrombopag for the promotion of platelet engraftment after Allo-HSCT.

Clinical Trial Description

Patients with thrombocytopenia (PLT<20×10^9/L) after allogenic hematopoietic stem cell transplantation (Allo-HSCT) who meet Eligibility Criteria were assigned into the avatrombopag group for 4 weeks' treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05143892
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Yue Han, MD PhD
Phone	(0086)51267781856
Email	hanyue@suda.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	December 1, 2021
Completion date	November 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05985668` - Towards Improved Diagnostics for Suspected Platelet Function Disorders
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT02979158` - Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass	N/A
Recruiting	`NCT04842760` - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Completed	`NCT01880047` - Safety and Efficacy of Eltrombopag at Escalated Doses	Phase 2
Withdrawn	`NCT04312789` - Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant	Phase 2